Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y463
UPID:
DYR1B_HUMAN
Alternative names:
Minibrain-related kinase; Mirk protein kinase
Alternative UPACC:
Q9Y463; O75258; O75788; O75789
Background:
Dual specificity tyrosine-phosphorylation-regulated kinase 1B, also known as Minibrain-related kinase and Mirk protein kinase, plays a pivotal role in various cellular processes. It is involved in ribosomal DNA repair, transcription silencing during DNA damage, and enhances the transcriptional activity of key transcription factors. Moreover, it inhibits epithelial cell migration and mediates cell survival in low mitogen environments.
Therapeutic significance:
Given its involvement in abdominal obesity-metabolic syndrome 3, characterized by early-onset coronary artery disease, central obesity, hypertension, and diabetes, understanding the role of Dual specificity tyrosine-phosphorylation-regulated kinase 1B could open doors to potential therapeutic strategies.